Company intelligence / Profile preview
Hepanova, Inc.
Gaithersburg, Maryland, United Stateshepanova.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hepanova, Inc. is a private clinical-stage biopharmaceutical company focused on developing innovative therapeutics for chronic liver diseases including NASH, liver fibrosis, hepatitis B/C, and hepatocellular carcinoma. Its lead candidate HPN‑01 targets SREBF1/SREBP‑2 and has completed or initiated a Phase 1 study evaluating safety and pharmacokinetics in healthy volunteers. The company remains early-stage with no approved products or late-phase assets as of early/mid–2025.
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Hepanova, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepanova, Inc..